Position in LYEL
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$0
New position
Shares Held
0
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Derivatives in LYEL
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$200
PutShares
10
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Persistent Asset Partners Ltd holds $59,316,956 across 109 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
133,066 | $4,329,967 | |
| 2 | COGT |
Cogent Biosciences, Inc.
|
92,516 | $3,560,940 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
15,905 | $3,006,840 | |
| 4 | ABVX |
Abivax S.A.
|
22,838 | $2,543,011 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
26,043 | $2,532,681 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
45,953 | $2,422,642 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
37,472 | $2,116,793 | |
| 8 | KOD |
Kodiak Sciences Inc.
|
51,336 | $1,956,928 |
All Filings in LYEL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $200 | 10 | Put | Sole | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||